Compare AbCellera Biologics Inc (ABCL) vs Tenet Healthcare Corporation (THC) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbCellera Biologics Inc vs Tenet Healthcare Corporation — how do they compare? AbCellera Biologics Inc trades at $7.15 (market cap $2.35B), while Tenet Healthcare Corporation trades at $206.47 (market cap $17.76B). The key difference: Tenet Healthcare Corporation is far larger — about 7.6× AbCellera Biologics Inc's market cap, and AbCellera Biologics Inc is trading nearer its 52-week high, Tenet Healthcare Corporation nearer its low. Which is the better fit depends on your goals.
| ABCL | THC | |
|---|---|---|
Market Cap | $2.35B | $17.76B |
Sector | Health | Health |
52-Week High | $8.12 | $244.80 |
52-Week Low | $2.78 | $148.38 |
Enterprise Value | $1.99B | $28.00B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbCellera Biologics (ABCL) trades at $7.69, down 5.18% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$146.41M in 2025, with negative margins, though revenue grew to $75.13M. Recent news highlights a major collaboration with Jazz Pharmaceuticals worth up to $876M, potentially boosting future revenue streams. Analyst consensus is strongly bullish with a $9.67 price target, indicating 25.7% upside.
The outlook hinges on execution of new partnerships and pipeline progress, particularly ABCL635 Phase 2 data expected in Q3 2026. Key risks include persistent cash burn, high valuation multiples despite losses, and biotech sector volatility. Investors should weigh the strong analyst support against fundamental challenges and the stock's current technical overbought condition.
Tenet Healthcare (THC) trades at $206.19, up 1.21% today, with a bullish technical outlook supported by moving averages and strong analyst sentiment. The stock shows robust fundamentals with a P/E of 10.72, net income margin of 7.79%, and consistent earnings beats in recent quarters. Recent news highlights growth in outpatient care and positive market performance amid broader dips.
Outlook remains positive with an 81.25% analyst buy rating and $233.38 consensus price target, though overbought RSI signals near-term caution. Risks include healthcare regulatory pressures and debt levels, but expanding admissions and solid cash flow support long-term upside for value and growth investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About Tenet Healthcare Corporation
Tenet Healthcare is a leading diversified healthcare services company that has strategically pivoted toward high-growth ambulatory care. Operating through United Surgical Partners International (USPI), the largest ambulatory platform in the U.S., Tenet manages an expansive network of surgical centers, acute care hospitals, and specialty facilities. The company’s focus on high-acuity services and operational efficiency, supported by its revenue cycle management subsidiary Conifer Health Solutions, positions it as a resilient leader in the evolving U.S. healthcare landscape.
Read more on THC →
